BACKGROUND: XRCC1 is a multi-domain protein associated with bladder cancer. We investigated the relationship between the distribution of XRCC1 polymorphisms (rs915927 and rs2854501) and clinical outcomes following intravesical instillation with epirubicin (EPI) or mitomycin C (MMC). METHODS: A TaqMan assay was performed to determine genotypes of 240 individuals diagnosed with bladder cancer. Logistic regression was used to assess the association between polymorphisms and relapse-free survival (RFS) of patients. Quantitative real-time polymerase chain reaction was performed to determine expression of XRCC1 polymorphisms. Survival curves were generated using the Kaplan-Meier method. RESULTS: Risk of bladder cancer recurrence was significantly reduced in patients receiving EPI who had higher incidences of XRCC1 polymorphisms (P=0.009 for rs915927, P=0.001 for rs2854501). In participants administered MMC, results were not statistically significant. CONCLUSIONS: Polymorphisms in XRCC1 SNP variants (rs915927 and rs2854501) were associated with improved clinical outcomes following EPI treatment.
BACKGROUND:XRCC1 is a multi-domain protein associated with bladder cancer. We investigated the relationship between the distribution of XRCC1 polymorphisms (rs915927 and rs2854501) and clinical outcomes following intravesical instillation with epirubicin (EPI) or mitomycin C (MMC). METHODS: A TaqMan assay was performed to determine genotypes of 240 individuals diagnosed with bladder cancer. Logistic regression was used to assess the association between polymorphisms and relapse-free survival (RFS) of patients. Quantitative real-time polymerase chain reaction was performed to determine expression of XRCC1 polymorphisms. Survival curves were generated using the Kaplan-Meier method. RESULTS: Risk of bladder cancer recurrence was significantly reduced in patients receiving EPI who had higher incidences of XRCC1 polymorphisms (P=0.009 for rs915927, P=0.001 for rs2854501). In participants administered MMC, results were not statistically significant. CONCLUSIONS: Polymorphisms in XRCC1 SNP variants (rs915927 and rs2854501) were associated with improved clinical outcomes following EPI treatment.
Authors: Somali Sanyal; Petra J De Verdier; Gunnar Steineck; Per Larsson; Erik Onelöv; Kari Hemminki; Rajiv Kumar Journal: Acta Oncol Date: 2007 Impact factor: 4.089
Authors: Carlotta Sacerdote; Simonetta Guarrera; Fulvio Ricceri; Barbara Pardini; Silvia Polidoro; Alessandra Allione; Rossana Critelli; Alessia Russo; Angeline S Andrew; Yuanqing Ye; Xifeng Wu; Lambertus A Kiemeney; Andrea Bosio; Giovanni Casetta; Giuseppina Cucchiarale; Paolo Destefanis; Paolo Gontero; Luigi Rolle; Andrea Zitella; Dario Fontana; Paolo Vineis; Giuseppe Matullo Journal: Int J Cancer Date: 2013-04-25 Impact factor: 7.396
Authors: Nadezda Lipunova; Anke Wesselius; Kar K Cheng; Frederik J van Schooten; Jean-Baptiste Cazier; Richard T Bryan; Maurice P Zeegers Journal: Biomark Cancer Date: 2019-12-30